This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
by Ekta Bagri
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
International Markets and Exelixis (EXEL): A Deep Dive for Investors
by Zacks Equity Research
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
by Zacks Equity Research
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 7.84% and 0.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHSC
Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines
by Zacks Equity Research
Pilgrim's Pride, Exelixis, Synchrony and United Airlines have been highlighted in this Screen of The Week article.
EXEL or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets
by Urmimala Biswas
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria.
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Exelixis (EXEL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHSC
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
by Zacks Equity Research
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Here's Why Exelixis (EXEL) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novartis to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
by Zacks Equity Research
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study.